Radiomic spatial maps for identifying viable tumor extent on multi-parametric MRI for glioblastoma
Active Project Grant Awarded Last action
- Award ID
- R01CA277728
- Recipient
-
University Of Wisconsin System UEI LCLSJAGTNZQ7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,953,744
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 48% complete
- Place of performance
- Madison, WI 53715, USA
Award details come from USAspending.gov.
Description
- Abstract
- Glioblastoma (GBM) has a complex infiltrating tumor microenvironment which extends well beyond the visible enhancing tumor margins and plays a substantial role in GBM recurrence and poor outcomes. Unfortunately, in the absence of a precise spatial map of tumor extent, IT is often difficult to differentiate infiltrating tumor from vasogenic edema on clinical MRI during radiation/surgical planning. The untreated infiltrating tumor ultimately contributes to over 90% of GBM recurrences. An equally pressing challenge is the difficulty in distinguishing recurrent tumor from treatment-effects following chemoradiation. Due to the histologically diverse landscape of post-treated lesions, treatment-effects often CO-exist with tumor recurrence, and mimic appearance on imaging. In the absence of reliable tools, 15-20% of patients with GBM recurrence are incorrectly diagnosed due to sampling error associated with intracranial biopsy. Thus, developing a non-invasive spatial map of GBM tumor extent that can reliably identify infiltrating/recurrent tumor from confounding pathologies (treatment- effects/edema), will have significant implications in radiation/surgical-planning and post-treatment management. Recently, we developed a radiomic-image (RAD-I) map of tumor extent that uses computational features corresponding to the micro-architectural image measurements of disorder in the local intensity gradients (i.e., gradient entropy). The initial version of the RAD-I map has been evaluated to distinguish recurrent tumors versus treatment-effects on post-treatment GD-T1W MRI with an 85% accuracy on N=75 studies, and to distinguish infiltrating tumor versus vasogenic edema on pre-treatment MRI scans with a 94% accuracy on N=42 studies. In this R01 project, we propose to improve on our initial version of RAD-I map by incorporating (1) additional anatomical (T2W, flair) and functional MR sequences (PERFUSION) and (2) a novel "lesion complexity" feature, which captures organizational changes in the tissue composition via graph-theoretic approaches on MRI scans. Overcoming limitations pertaining to small cohorts and lack of spatially mapped EX-vivo histology for validation, RAD-I maps will be extensively validated on (1) a large multi-institutional MRI cohort with CO-localized histopathology and (2) the preserve clinical trial designed to capture GBM heterogeneity via multiple CO- localized tissue samples/lesion. These cohorts will also allow for establishing associations of our new radiomic features with underlying histological/molecular tumor characteristics- a prerequisite for clinical adoption. Lastly, RAD-I maps will be evaluated within a tumor board survey to address the clinically challenging problem of distinguishing recurrent tumors versus treatment effects. Criteria for success for RAD-I maps are that they are at least non-inferior to the accuracy of stereotactic biopsies (85-90%) in identifying tumor niches corresponding to (a) viable/infiltrating tumor VS. Edema and (B) recurrent tumor VS. Treatment effects. Multi-institutional validation and end-user (tumor board) feedback will further confirm the utility of RAD-I maps as a noninvasive alternative to surgical biopsies; thereby paving the way for radiation/surgical and post-treatment management in GBM tumors.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,727,337 | |
| Amendment | $0 | |
| Amendment | $586,765 | |
| Original award | $639,642 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Baptist Health South Florida, Inc. | $174,396 | |
| H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. | $67,272 | |
| Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University | $124,834 |
Quick answers
Who received award R01CA277728?
R01CA277728 was awarded to University Of Wisconsin System by National Cancer Institute (National Institutes of Health) on June 1, 2024.
How much is award R01CA277728 worth?
$2,953,744 has been obligated on R01CA277728.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award